ClinicalTrials.gg
CompletedNCT00095498Updated Oct 25, 2021Results posted

Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis

A Phase 2 interventional study of placebo and denosumab in Rheumatoid Arthritis, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-25.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
227
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 57 studies in Arthritis, Rheumatoid by Amgen — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Amgen.

Enrollment
18th of 47
227 · median 211
Started
2004
with 2 others
Phase 2
14 of 57
1 open now
Registered
4th of 57
by date

Among the 57 studies in Arthritis, Rheumatoid by Amgen, this one is the 18th largest by enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2004, is one of 14 in phase 2, and was the 4th registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

1 of the 57 studies in Arthritis, Rheumatoid by Amgen is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Arthritis, Rheumatoid by Amgen, or all of them as a file.
02

Study summary

This study will determine the efficacy, safety, and tolerability of denosumab (AMG 162) in the treatment of Rheumatoid Arthritis (RA).

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • arthritis
  • joint pain
  • Methotrexate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of RA.
  • All subjects will be required to have been taking a stable dose of methotrexate.
  • Active RA at screening defined as greater than or equal to 6 swollen joints.
  • The presence of erosive disease

Exclusion criteria

Exclusion Criteria:

  • Received any biologic agent (e.g., Enbrel®, Remicade®, Humira®, Kineret®) or Arava® within 8 weeks before randomization; past use of these agents is allowed.
  • use greater than 15 mg/day.
  • Scheduled for surgery or joint replacement in the hands, wrists or feet.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
227 participants (actual)

Study arms

  • Experimental
    Denosumab 180 mg

    Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.

    Drug: denosumab

  • Experimental
    Denosumab 60 mg

    Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.

    Drug: denosumab

  • Placebo comparator
    Placebo

    Participants received placebo subcutaneous injections on Day 1 and at Month 6.

    Drug: placebo

Interventions

  • Drugplacebo

    placebo subcutaneous injection

  • For subcutaneous injection

    Also known as: AMG 162

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Rheumatoid Arthritis Erosion Score Measured From MRI Assessments (RA-MRI ES) at Month 6

    Fifteen sites in each wrist and 10 sites in each hand were assessed by a blinded and independent reader. Each site was scored from 0 to 10 (in accordance with the European League Against Rheumatism \[EULAR\]-Outcome Measures in Rheumatology Clinical Trials convention), with each unit increment representing 10% incremental loss of the peripheral 1 cm of articular bone. The Erosion Score is a sum of erosion scores from 50 joint sites in both hands/wrists and ranges from 0 (normal, no erosion) to 500 (worst possible erosion).

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 12

    TSS is the sum of erosion and joint space narrowing scores obtained from radiographs of the hands and feet, assessed by 2 independent readers. The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280. Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. The TSS ranged from 0 (normal) to 448 (worst).

    Time frame: Baseline, Month 12

  2. Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 6

    TSS is the sum of erosion and joint space narrowing scores obtained from radiographs of the hands and feet, assessed by 2 independent readers. The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280. Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. The TSS ranged from 0 (normal) to 448 (worst).

    Time frame: Baseline, Month 6

  3. Change From Baseline in Radiographic Erosion Score at Month 12

    The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet, obtained from radiographs of the hands and feet and assessed by 2 independent readers. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280.

    Time frame: Baseline, Month 12

  4. Change From Baseline in Radiographic Erosion Score at Month 6

    The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet, obtained from radiographs of the hands and feet and assessed by 2 independent readers. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280.

    Time frame: Baseline, Month 6

  5. Change From Baseline in Radiographic Joint Space Narrowing Score at Month 12

    Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet obtained from radiographs of the hands and feet and assessed by 2 independent readers. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score (indicating worst joint space narrowing) of 168.

    Time frame: Baseline, Month 12

  6. Change From Baseline in Radiographic Joint Space Narrowing Score at Month 6

    Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet obtained from radiographs of the hands and feet and assessed by 2 independent readers. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score (indicating worst joint space narrowing) of 168.

    Time frame: Baseline, Month 6

  7. Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 1

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((month 1 value - baseline value) / baseline value ) x 100. Least squares means are based on a repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

    Time frame: Baseline, Month 1

  8. Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 6

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to month 6 calculated using ((month 6 value - baseline value) / baseline value ) x 100. Least squares means are based on a repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

    Time frame: Baseline, month 6

  9. Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

    Time frame: Baseline, Month 12

  10. Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 1

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((Month 1 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

    Time frame: Baseline, Month 1

  11. Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 6

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 6 calculated using ((Month 6 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

    Time frame: Baseline, Month 6

  12. Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

    Time frame: Baseline, Month 12

  13. Percent Change From Baseline in Total Hip Bone Mineral Density at Month 1

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((Month 1 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

    Time frame: Baseline, Month 1

  14. Percent Change From Baseline in Total Hip Bone Mineral Density at Month 6

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 6 calculated using ((Month 6 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

    Time frame: Baseline, Month 6

  15. Percent Change From Baseline in Total Hip Bone Mineral Density at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

    Time frame: Baseline, Month 12

  16. Percent Change From Baseline in Serum Collagen C-Telopeptide (CTX) at Month 3

    Percent change from baseline to Month 3 in serum Collagen C-Telopeptide (CTX) Type I calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline, Month 3

  17. Percent Change From Baseline in Serum CTX at Month 6

    Percent change from baseline to Month 6 in serum Collagen C-Telopeptide (CTX) Type I calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline, Month 6

  18. Percent Change From Baseline in Serum CTX at Month 12

    Percent change from Baseline to Month 12 in serum C-Telopeptide (CTX) Type I calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline, Month 12

  19. Percent Change From Baseline in Procollagen 1 N-terminal Peptide (P1NP) at Month 3

    Percent change from baseline to Month 3 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline, Month 3

  20. Percent Change From Baseline in P1NP at Month 6

    Percent change from baseline to Month 6 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline, Month 6

  21. Percent Change From Baseline in P1NP at Month 12

    Percent change from baseline to Month 12 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline, Month 12

  22. Percent Change From Baseline in Urine Type II Collagen C-telopeptide (C-Tx) /Creatinine at Month 3

    Percent change from baseline to Month 3 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline, Month 3

  23. Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 6

    Percent change from baseline to Month 6 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline, Month 6

  24. Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 12

    Percent change from baseline to Month 12 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

    Time frame: Baseline, Month 12

  25. Number of Participants With Anti-Denosumab Binding Antibodies

    Serum from participants was tested for antibodies to denosumab by immuoassay at months 1, 3, 6 and 12. The number of participants with anti-denosumab antibodies at any assessment is reported.

    Time frame: Assessed at Baseline and at Months 1, 3, 6 and 12.

  26. Number of Participants With Anti-Denosumab Binding Antibody and Neutralizing Antibody

    Serum from participants testing positive for anti-denosumab binding antibodies was tested in a cell-based bioassay for neutralizing activity against denosumab.

    Time frame: Baseline to Month 12

  27. Change From Baseline in Albumin at Month 1

    Laboratory Chemistry Albumin

    Time frame: Baseline, month 1

  28. Change From Baseline in Albumin at Month 3

    Laboratory chemistry albumin

    Time frame: Baseline, month 3

  29. Change From Baseline in Albumin at Month 6

    Laboratory chemistry albumin

    Time frame: Baseline, month 6

  30. Change From Baseline in Albumin at Month 12

    Laboratory chemistry albumin

    Time frame: Baseline, month 12

  31. Change From Baseline in Alkaline Phosphatase at Month 1

    Laboratory chemistry alkaline phoshatatse

    Time frame: Baseline, month 1

  32. Change From Baseline in Alkaline Phosphatase at Month 3

    Laboratory chemisrty alkaline phosphatase

    Time frame: baseline, month 3

  33. Change From Baseline in Alkaline Phosphatase at Month 6

    Laboratory chemistry alkaline phosphatase

    Time frame: baseline, month 6

  34. Change From Baseline in Alkaline Phosphatase at Month 12

    Laboratory chemistry alkaline phosphatase

    Time frame: baseine, month 12

  35. Change From Baseline in Bicarbonate at Month 1

    Laboratory chemistry bicarbonate

    Time frame: baseline, month 1

  36. Change From Baseline in Bicarbonate at Month 3

    Laboratory chemistry bicarbonate

    Time frame: baseline, month 3

  37. Change From Baseline in Bicarbonate at Month 6

    Laboratory chemistry bicarbonate

    Time frame: Baseline, month 6

  38. Change From Baseline in Bicarbonate at Month 12

    Laboratory chemistry bicarbonate

    Time frame: Baseline, Month 12

  39. Change From Baseline in Total Bilirubin at Month 1

    Laboratory chemistry total bilirubin

    Time frame: baseline, month 1

  40. Change From Baseline in Total Bilirubin at Month 3

    Laboratory chemistry total bilirubin

    Time frame: Baseline, month 3

  41. Change From Baseline in Total Bilirubin at Month 6

    Laboratory chemistry total bilirubin

    Time frame: Baseline, month 6

  42. Change From Baseline in Total Bilirubin at Month 12

    Laboratory chemistry total bilirubin

    Time frame: Baseline, month 12

  43. Change From Baseline in Blood Urea Nitrogen at Month 1

    Laboratory chemistry blood urea nitrogen

    Time frame: Baseline, month 1

  44. Change From Baseline in Blood Urea Nitrogen at Month 3

    Laboratory chemistry blood urea nitrogen

    Time frame: Baseline, month 3

  45. Change From Baseline in Blood Urea Nitrogen at Month 6

    Laboratory chemistry blood urea nitrogen

    Time frame: Baseline, month 6

  46. Change From Baseline in Blood Urea Nitrogen at Month 12

    Laboratory chemistry blood urea nitrogen

    Time frame: baseline, month 12

  47. Change From Baseline in Calcium at Month 1

    Laboratory chemistry calcium

    Time frame: baseline. month 1

  48. Change From Baseline in Calcium at Month 3

    Laboratory chemistry calcium

    Time frame: Baseline, month 3

  49. Change From Baseline in Calcium at Month 6

    Laboratory chemistry calcium

    Time frame: baseline, month 6

  50. Change From Baseline in Calcium at Month 12

    Laboratory chemistry calcium

    Time frame: Baseline, month 12

  51. Change From Baseline in Calcium (Corrected) at Month 1

    Laboratory chemistry albumin-adjusted calcium

    Time frame: Baseline, month 1

  52. Change From Baseline in Calcium (Corrected) at Month 3

    Laboratory chemistry albumin-adjusted calcium

    Time frame: baseline, month 3

  53. Change From Baseline in Calcium (Corrected) at Month 6

    Laboratory chemistry albumin-adjusted calcium

    Time frame: Baseline, Month 6

  54. Change From Baseline in Calcium (Corrected) at Month 12

    Laboratory chemistry albumin-adjusted calcium

    Time frame: Baselien, Month 12

  55. Change From Baseline in Chloride at Month 1

    Laboratory chemistry chloride

    Time frame: baseline, month 1

  56. Change From Baseline in Chloride at Month 3

    Laboratory chemistry chloride

    Time frame: Baseline, month 3

  57. Change From Baseline in Chloride at Month 6

    Laboratory chemistry chloride

    Time frame: Baseline, month 6

  58. Change From Baseline in Chloride at Month 12

    Laboratory chemistry chloride

    Time frame: Baseline, month 12

  59. Change From Baseline in Creatinine at Month 1

    Laboratory chemistry creatinine

    Time frame: Baseline, month 1

  60. Change From Baseline in Creatinine at Month 3

    Laboratory chemistry creatinine

    Time frame: Baseline, month 3

  61. Change From Baseline in Creatinine at Month 6

    Laboratory chemistry creatinine

    Time frame: Baseline, month 6

  62. Change From Baseline in Creatinine at Month 12

    Laboratory chemistry creatinine

    Time frame: Baseline, month 12

  63. Change From Baseline in Gamma-Glutamyl Transferase at Month 1

    Laboratory chemistry gamma-glutamyl transferase

    Time frame: Baseline, month 1

  64. Change From Baseline in Gamma-Glutamyl Transferase at Month 3

    Laboratory chemistry gamma-glutamyl transferase

    Time frame: Baseline, month 3

  65. Change From Baseline in Gamma-Glutamyl Transferase at Month 6

    Laboratory chemistry gamma-glutamyl transferase

    Time frame: Baseline, month 6

  66. Change From Baseline in Gamma-Glutamyl Transferase at Month 12

    Laboratory chemistry gamma-glutamyl transferase

    Time frame: Baseline, month 12

  67. Change From Baseline in Glucose at Month 1

    Laboratory chemistry glucose

    Time frame: Baseline, month 1

  68. Change From Baseline in Glucose at Month 3

    Laboratory chemistry glucose

    Time frame: Baseline, month 3

  69. Change From Baseline in Glucose at Month 6

    Laboratory chemistry glucose

    Time frame: Baseline, month 6

  70. Change From Baseline in Glucose at Month 12

    Laboratory chemistry glucose

    Time frame: baseline, month 12

  71. Change From Baseline in Potassium at Month 1

    Laboratory chemistry potassium

    Time frame: Baseline, month 1

  72. Change From Baseline in Potassium at Month 3

    Laboratory chemistry potassium

    Time frame: Baseline, month 3

  73. Change From Baseline in Potassium at Month 6

    Laboratory chemistry potassium

    Time frame: Baseline, month 6

  74. Change From Baseline in Potassium at Month 12

    Laboratory chemistry potassium

    Time frame: Baseline, month 12

  75. Change From Baseline in Magnesium at Month 1

    Laboratory chemistry magnesium

    Time frame: Baseline, month 1

  76. Change From Baseline in Magnesium at Month 3

    Laboratory chemistry magnesium

    Time frame: Baseline, month 3

  77. Change From Baseline in Magnesium at Month 6

    Laboratory chemistry magnesium

    Time frame: Baseline, month 6

  78. Change From Baseline in Magnesium at Month 12

    Laboratory chemistry magnesium

    Time frame: Baseline, month 12

  79. Change From Baseline in Sodium at Month 1

    Laboratory chemistry sodium

    Time frame: Baseline, month 1

  80. Change From Baseline in Sodium at Month 3

    Change From Baseline in Sodium at Month 3

    Time frame: Baseline, Month 3

  81. Change From Baseline in Sodium at Month 6

    Laboratory chemistry sodium

    Time frame: Baseline, month 6

  82. Change From Baseline in Sodium at Month 12

    Laboratory chemistry sodium

    Time frame: Baseline, month 12

  83. Change From Baseline in Phosphorus at Month 1

    Laboratory chemistry phosphorus

    Time frame: Baseline, month 1

  84. Change From Baseline in Phosphorus at Month 3

    Laboratory chemistry phosphorus

    Time frame: Baseline, month 3

  85. Change From Baseline in Phosphorus at Month 6

    Laboratory chemistry phosphorus

    Time frame: Baseline, month 6

  86. Change From Baseline in Phosphorus at Month 12

    Change From Baseline in Phosphorus at Month 12

    Time frame: Baseline, month 12

  87. Change From Baseline in Total Protein at Month 1

    Laboratory chemistry total protein

    Time frame: Baseline, month 1

  88. Change From Baseline in Total Protein at Month 3

    Laboratory chemistry total protein

    Time frame: Baseline, month 3

  89. Change From Baseline in Total Protein at Month 6

    Laboratory chemistry total protein

    Time frame: Baseline, month 6

  90. Change From Baseline in Total Protein at Month 12

    Laboratory chemistry total protein

    Time frame: Baseline, month 12

  91. Change From Baseline in Aspartate Amino Transferase at Month 1

    Laboratory chemistry aspartate amino transferase

    Time frame: Baseline, month 1

  92. Change From Baseline in Aspartate Amino Transferase at Month 3

    Laboratory chemistry aspartate amino transferase

    Time frame: Baseline, month 3

  93. Change From Baseline in Aspartate Amino Transferase

    Laboratory chemistry aspartate amino transferase

    Time frame: Baseline, month 6

  94. Change From Baseline in Aspartate Amino Transferase at Month 12

    Laboratory chemistry aspartate amino transferase

    Time frame: Baseline, month 12

  95. Change From Baseline in Alanine Amino Transferase at Month 1

    Laboratory chemistry alanine amino transferase

    Time frame: Baseline, month 1

  96. Change From Baseline in Alanine Amino Transferase at Month 3

    Laboratory Chemistry alanine amino transferase

    Time frame: Baseline, month 3

  97. Change From Baseline in Alanine Amino Transferase at Month 6

    Laboratory chemistry alanine amino transferase

    Time frame: Baseline, month 6

  98. Change From Baseline in Alanine Amino Transferase at Month 12

    Laboratory chemistry alanine amino transferase

    Time frame: Baseline, month 12

  99. Change From Baseline in Basophils at Month 1

    Laboratory hematology basophils

    Time frame: baseline, month 1

  100. Change From Baseline in Basophils at Month 3

    Laboratory hematology basophils

    Time frame: Baseline, month 3

  101. Change From Baseline in Basophils at Month 6

    Laboratory hematology basophils

    Time frame: Baseline, month 6

  102. Change From Baseline in Basophils at Month 12

    Laboratory hematology basophils

    Time frame: Baseline, month 12

  103. Change From Baseline in Eosinophils at Month 1

    Laboratory hematology eosinophils

    Time frame: Baseline, month 1

  104. Change From Baseline in Eosinophils at Month 3

    Laboratory hematology eosinophils

    Time frame: Baseline, month 3

  105. Change From Baseline in Eosinophils at Month 6

    Laboratory hematology eosinophils

    Time frame: Baseline, month 6

  106. Change From Baseline in Eosinophils at Month 12

    Laboratory hematology eosinophils

    Time frame: Baseline, month 12

  107. Change From Baseline in Hematocrit at Month 1

    Laboratory hematology hematocrit

    Time frame: Baseline, month 1

  108. Change From Baseline in Hematocrit at Month 3

    Laboratory hematology hematocrit

    Time frame: Baseline, month 3

  109. Change From Baseline in Hematocrit at Month 6

    Laboratory hematology hematocrit

    Time frame: Baseline, month 6

  110. Change From Baseline in Hematocrit at Month 12

    Laboratory hematology hematocrit

    Time frame: Baseline, month 12

  111. Change From Baseline in Hemoglobin at Month 1

    Laboratory hematology hemoglobin

    Time frame: Baseline, month 1

  112. Change From Baseline in Hemoglobin at Month 3

    Laboratory hematology hemoglobin

    Time frame: Baseline, month 3

  113. Change From Baseline in Hemoglobin at Month 6

    Laboratory hematology hemoglobin

    Time frame: Baseline, month 6

  114. Change From Baseline in Hemoglobin at Month 12

    Laboratory hematology hemoglobin

    Time frame: Baseline, month 12

  115. Change From Baseline in Lymphocytes at Month 1

    Laboratory hematology lymphocytes

    Time frame: Baseline, month 1

  116. Change From Baseline in Lymphocytes at Month 3

    Laboratory hematology lymphocytes

    Time frame: Baseline, month 3

  117. Change From Baseline in Lymphocytes at Month 6

    Laboratory hematology lymphocytes

    Time frame: Baseline, month 6

  118. Change From Baseline in Lymphocytes at Month 12

    Laboratory hematology lymphocytes

    Time frame: Baseline, month 12

  119. Change From Baseline in Monocytes at Month 1

    Laboratory hematology monocytes

    Time frame: Baseline, month 1

  120. Change From Baseline in Monocytes at Month 3

    Laboratory hematology monocytes

    Time frame: Baseline, month 3

  121. Change From Baseline in Monocytes at Month 6

    Laboratory hematology monocytes

    Time frame: Baseline, month 6

  122. Change From Baseline in Monocytes at Month 12

    Laboratory hematology monocytes

    Time frame: Baseline, month 12

  123. Change From Baseline in Total Neutrophils at Month 1

    Laboratory hematology total neutrophils

    Time frame: Baseline, month 1

  124. Change From Baseline in Total Neutrophils at Month 3

    Laboratory hematology total neutrophils

    Time frame: Baseline, month 3

  125. Change From Baseline in Total Neutrophils at Month 6

    Laboratory hematology total neutrophils

    Time frame: Baseline, month 6

  126. Change From Baseline in Total Neutrophils at Month 12

    Laboratory hematology total neutrophils

    Time frame: Baseline, month 12

  127. Change From Baseline in Platelets at Month 1

    Laboratory hematology platelets

    Time frame: Baseline, month 1

  128. Change From Baseline in Platelets at Month 3

    Laboratory hematology platelets

    Time frame: Baseline, month 3

  129. Change From Baseline in Platelets at Month 6

    Laboratory hematology platelets

    Time frame: Baseline, month 6

  130. Change From Baseline in Platelets at Month 12

    Laboratory hematology platelets

    Time frame: Baseline, month 12

  131. Change From Baseline in Red Blood Cells at Month 1

    Laboratory hematology red blood cells

    Time frame: Baseline, month 1

  132. Change From Baseline in Red Blood Cells at Month 3

    Laboratory hematology red blood cells

    Time frame: Baseline, month 3

  133. Change From Baseline in Red Blood Cells at Month 6

    Laboratory hematology red blood cells

    Time frame: Baseline, month 6

  134. Change From Baseline in Red Blood Cells at Month 12

    Laboratory hematology red blood cells

    Time frame: Baseline, month 12

  135. Change From Baseline in White Blood Cells at Month 1

    Laboratory hematology white blood cells

    Time frame: Baseline, month 1

  136. Change From Baseline in White Blood Cells at Month 3

    Laboratpry hematology white blood cells

    Time frame: Baseline, month 3

  137. Change From Baseline in White Blood Cells at Month 6

    Laboratory hematology white blood cells

    Time frame: Baseline, month 6

  138. Change From Baseline in White Blood Cells at Month 12

    Laboratory hematology white blood cells

    Time frame: Baseline, month 12

  139. Number of Participants With Laboratory Common Terminology Criteria for Adverse Events (CTCAE) Grade Greater or Equal to 3

    Participants with laboratory toxicity of grade 3 or 4, graded according to the Common Terminology Criteria for Adverse Events, version 3.0, on the following general guideline: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death related to AE.

    Time frame: Month 1, month 3, month 6, month 12

07

Results

Posted Jan 13, 2014

Participant flow

First Subject Enrolled: 11-Aug-2004 Last Subject Enrolled: 07-Apr-2005

Participant flow — Overall Study
MilestoneDenosumab 180 mgDenosumab 60 mgPlacebo
Started767378
Received investigational product727175
Completed393839
Not completed373539
Withdrew: Physician decision9108
Withdrew: Adverse event101
Withdrew: Withdrawal by subject151615
Withdrew: Disease progression011
Withdrew: Ineligibility determined302
Withdrew: Lost to follow-up112
Withdrew: Noncompliance101
Withdrew: Other676
Withdrew: Protocol violation001
Withdrew: Requirement for alternative therapy102

Outcome measures

PrimaryChange From Baseline in Rheumatoid Arthritis Erosion Score Measured From MRI Assessments (RA-MRI ES) at Month 6

Fifteen sites in each wrist and 10 sites in each hand were assessed by a blinded and independent reader. Each site was scored from 0 to 10 (in accordance with the European League Against Rheumatism \[EULAR\]-Outcome Measures in Rheumatology Clinical Trials convention), with each unit increment representing 10% incremental loss of the peripheral 1 cm of articular bone. The Erosion Score is a sum of erosion scores from 50 joint sites in both hands/wrists and ranges from 0 (normal, no erosion) to 500 (worst possible erosion).

Time frame:
Baseline, Month 6
Reported as:
Median · units on a scale
Change From Baseline in Rheumatoid Arthritis Erosion Score Measured From MRI Assessments (RA-MRI ES) at Month 6
units on a scaleDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Rheumatoid Arthritis Erosion Score Measured From MRI Assessments (RA-MRI ES) at Month 60.00 ± 3.490.00 ± 3.430.49 ± 5.08
Statistical analysis
  • Denosumab 60 mg vs Placebo · van Elteren stratified rank test · p = 0.264
  • Denosumab 180 mg vs Placebo · van Elteren stratified rank test · p = 0.018
SecondaryChange From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 12

TSS is the sum of erosion and joint space narrowing scores obtained from radiographs of the hands and feet, assessed by 2 independent readers. The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280. Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. The TSS ranged from 0 (normal) to 448 (worst).

Time frame:
Baseline, Month 12
Reported as:
Median · units on a scale
Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 12
units on a scaleDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 120 (0 to 1.5)0 (-0.5 to 1)0.5 (0 to 2)
Statistical analysis
  • Denosumab 60 mg vs Placebo · van Elteren Stratified Rank Test · p = 0.032
  • Denosumab 180 mg vs Placebo · van Elteren Stratified Rank Test · p = 0.180
SecondaryChange From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 6

TSS is the sum of erosion and joint space narrowing scores obtained from radiographs of the hands and feet, assessed by 2 independent readers. The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280. Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. The TSS ranged from 0 (normal) to 448 (worst).

Time frame:
Baseline, Month 6
Reported as:
Median · units on a scale
Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 6
units on a scaleDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 60 (0 to 0.5)0 (0 to 1)0 (0 to 1)
Statistical analysis
  • Denosumab 60 mg vs Placebo · van Elteren Stratified Rank Test · p = 0.602
  • Denosumab 180 mg vs Placebo · van Elteren Stratified Rank Test · p = 0.181
SecondaryChange From Baseline in Radiographic Erosion Score at Month 12

The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet, obtained from radiographs of the hands and feet and assessed by 2 independent readers. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280.

Time frame:
Baseline, Month 12
Reported as:
Median · units on a scale
Change From Baseline in Radiographic Erosion Score at Month 12
units on a scaleDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Radiographic Erosion Score at Month 120 (0 to 0.5)0 (0 to 0.5)0 (0 to 1.5)
Statistical analysis
  • Denosumab 60 mg vs Placebo · van Elteren Stratified Rank Test · p = 0.012
  • Denosumab 180 mg vs Placebo · van Elteren Stratified Rank Test · p = 0.007
SecondaryChange From Baseline in Radiographic Erosion Score at Month 6

The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet, obtained from radiographs of the hands and feet and assessed by 2 independent readers. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280.

Time frame:
Baseline, Month 6
Reported as:
Median · units on a scale
Change From Baseline in Radiographic Erosion Score at Month 6
units on a scaleDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Radiographic Erosion Score at Month 60 (0 to 0)0 (0 to 0.5)0 (0 to 0.5)
Statistical analysis
  • Denosumab 60 mg vs Placebo · van Elteren Stratified Rank Test · p = 0.277
  • Denosumab 180 mg vs Placebo · van Elteren Stratified Rank Test · p = 0.019
SecondaryChange From Baseline in Radiographic Joint Space Narrowing Score at Month 12

Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet obtained from radiographs of the hands and feet and assessed by 2 independent readers. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score (indicating worst joint space narrowing) of 168.

Time frame:
Baseline, Month 12
Reported as:
Median · units on a scale
Change From Baseline in Radiographic Joint Space Narrowing Score at Month 12
units on a scaleDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Radiographic Joint Space Narrowing Score at Month 120 (0 to 1)0 (0 to 0.5)0 (0 to 1)
Statistical analysis
  • Denosumab 60 mg vs Placebo · van Elteren Stratified Rank Test · p = 0.382
  • Denosumab 180 mg vs Placebo · van Elteren Stratified Rank Test · p = 0.488
SecondaryChange From Baseline in Radiographic Joint Space Narrowing Score at Month 6

Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet obtained from radiographs of the hands and feet and assessed by 2 independent readers. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score (indicating worst joint space narrowing) of 168.

Time frame:
Baseline, Month 6
Reported as:
Median · units on a scale
Change From Baseline in Radiographic Joint Space Narrowing Score at Month 6
units on a scaleDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Radiographic Joint Space Narrowing Score at Month 60 (0 to 0.5)0 (0 to 0.97)0 (0 to 0.5)
Statistical analysis
  • Denosumab 60 mg vs Placebo · van Elteren Stratified Rank Test · p = 0.236
  • Denosumab 180 mg vs Placebo · van Elteren Stratified Rank Test · p = 0.712
SecondaryPercent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 1

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((month 1 value - baseline value) / baseline value ) x 100. Least squares means are based on a repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

Time frame:
Baseline, Month 1
Reported as:
Least squares mean · Percent change from baseline
Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 1
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 10.25 ± 0.290.59 ± 0.29-0.34 ± 0.29
Statistical analysis
  • Denosumab 60 mg vs Placebo · Repeated Measures Model · p = 0.026 · Mean difference (final values): 0.93 · 95% CI 0.11 to 1.74
  • Denosumab 180 mg vs Placebo · Repeated measures model · p = 0.155 · Mean difference (final values): 0.59 · 95% CI -0.23 to 1.41
SecondaryPercent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 6

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to month 6 calculated using ((month 6 value - baseline value) / baseline value ) x 100. Least squares means are based on a repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

Time frame:
Baseline, month 6
Reported as:
Least squares mean · Percent change from baseline
Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 6
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 62.61 ± 0.382.40 ± 0.370.73 ± 0.38
Statistical analysis
  • Denosumab 60 mg vs Placebo · Repeated Measures Model · p = 0.002 · Mean difference (final values): 1.67 · 95% CI 0.62 to 2.72
  • Denosumab 180 mg vs Placebo · Repeated Measures Model · p = <0.001 · Mean difference (final values): 1.89 · 95% CI 0.84 to 2.94
SecondaryPercent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · Percent change from baseline
Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 124.09 ± 0.403.00 ± 0.390.80 ± 0.40
Statistical analysis
  • Denosumab 60 mg vs Placebo · Repeated Measures Model · p = <0.001 · Mean difference (final values): 2.2 · 95% CI 1.1 to 3.29
  • Denosumab 180 mg vs Placebo · Repeated Measures Model · p = <0.001 · Mean difference (final values): 3.29 · 95% CI 2.18 to 4.39
SecondaryPercent Change From Baseline in Femoral Neck Bone Mineral Density at Month 1

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((Month 1 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

Time frame:
Baseline, Month 1
Reported as:
Least squares mean · Percent change from baseline
Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 1
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 10.64 ± 0.38-0.15 ± 0.38-0.16 ± 0.38
Statistical analysis
  • Denosumab 60 mg vs Placebo · Repeated Measures Model · p = 0.986 · Mean difference (final values): 0.01 · 95% CI -1.06 to 1.08
  • Denosumab 180 mg vs Placebo · Repeated Measures Model · p = 0.141 · Mean difference (final values): 0.8 · 95% CI -0.27 to 1.86
SecondaryPercent Change From Baseline in Femoral Neck Bone Mineral Density at Month 6

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 6 calculated using ((Month 6 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · Percent change from baseline
Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 6
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 60.84 ± 0.370.89 ± 0.37-0.06 ± 0.37
Statistical analysis
  • Denosumab 60 mg vs Placebo · Repeated Measures Model · p = 0.073 · Mean difference (final values): 0.95 · 95% CI -0.09 to 1.99
  • Denosumab 180 mg vs Placebo · Repeated Measures Model · p = 0.09 · Mean difference (final values): 0.89 · 95% CI -0.14 to 1.93
SecondaryPercent Change From Baseline in Femoral Neck Bone Mineral Density at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · Percent change from baseline
Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 12
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 121.51 ± 0.471.34 ± 0.47-0.47 ± 0.47
Statistical analysis
  • Denosumab 60 mg vs Placebo · Repeated Measures Model · p = 0.007 · Mean difference (final values): 1.81 · 95% CI 0.51 to 3.12
  • Denosumab 180 mg vs Placebo · Repeated Measures Model · p = 0.003 · Mean difference (final values): 1.98 · 95% CI 0.67 to 3.29
SecondaryPercent Change From Baseline in Total Hip Bone Mineral Density at Month 1

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((Month 1 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

Time frame:
Baseline, Month 1
Reported as:
Least squares mean · Percent change from baseline
Percent Change From Baseline in Total Hip Bone Mineral Density at Month 1
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in Total Hip Bone Mineral Density at Month 10.06 ± 0.220.00 ± 0.22-0.02 ± 0.22
Statistical analysis
  • Denosumab 60 mg vs Placebo · Repeated Measures Model · p = 0.938 · Mean difference (final values): 0.02 · 95% CI -0.58 to 0.63
  • Denosumab 180 mg vs Placebo · Repeated Measures Model · p = 0.787 · Mean difference (final values): 0.08 · 95% CI -0.53 to 0.69
SecondaryPercent Change From Baseline in Total Hip Bone Mineral Density at Month 6

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 6 calculated using ((Month 6 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · Percent change from baseline
Percent Change From Baseline in Total Hip Bone Mineral Density at Month 6
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in Total Hip Bone Mineral Density at Month 61.12 ± 0.240.95 ± 0.24-0.06 ± 0.24
Statistical analysis
  • Denosumab 60 mg vs Placebo · Repeated Measures Model · p = 0.004 · Mean difference (final values): 1 · 95% CI 0.33 to 1.67
  • Denosumab 180 mg vs Placebo · Repeated Measures Model · p = <0.001 · Mean difference (final values): 1.18 · 95% CI 0.51 to 1.85
SecondaryPercent Change From Baseline in Total Hip Bone Mineral Density at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · Percent change from baseline
Percent Change From Baseline in Total Hip Bone Mineral Density at Month 12
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in Total Hip Bone Mineral Density at Month 121.67 ± 0.331.56 ± 0.33-0.38 ± 0.33
Statistical analysis
  • Denosumab 60 mg vs Placebo · Repeated Measures Model · p = <0.001 · Mean difference (final values): 1.94 · 95% CI 1.02 to 2.85
  • Denosumab 180 mg vs Placebo · Repeated Measures Model · p = <0.001 · Mean difference (final values): 2.04 · 95% CI 1.13 to 2.96
SecondaryPercent Change From Baseline in Serum Collagen C-Telopeptide (CTX) at Month 3

Percent change from baseline to Month 3 in serum Collagen C-Telopeptide (CTX) Type I calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline, Month 3
Reported as:
Median · Percent change from baseline
Percent Change From Baseline in Serum Collagen C-Telopeptide (CTX) at Month 3
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in Serum Collagen C-Telopeptide (CTX) at Month 3-78.67 (-86.29 to -62.86)-80.46 (-86.27 to -66.84)-11.48 (-26.95 to 15.59)
Statistical analysis
  • Denosumab 60 mg vs Placebo · van Elteren Stratified Rank Test · p = <0.001
  • Denosumab 180 mg vs Placebo · van Elteren Stratified Rank Test · p = <0.001
SecondaryPercent Change From Baseline in Serum CTX at Month 6

Percent change from baseline to Month 6 in serum Collagen C-Telopeptide (CTX) Type I calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline, Month 6
Reported as:
Median · Percent change from baseline
Percent Change From Baseline in Serum CTX at Month 6
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in Serum CTX at Month 6-62.69 (-78.56 to -46.23)-50.64 (-63.31 to -22.37)-12.94 (-31.20 to 23.30)
Statistical analysis
  • Denosumab 60 mg vs Placebo · van Elteren Stratified Rank Test · p = <0.001
  • Denosumab 180 mg vs Placebo · van Elteren Stratified Rank Test · p = <0.001
SecondaryPercent Change From Baseline in Serum CTX at Month 12

Percent change from Baseline to Month 12 in serum C-Telopeptide (CTX) Type I calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline, Month 12
Reported as:
Median · Percent change from baseline
Percent Change From Baseline in Serum CTX at Month 12
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in Serum CTX at Month 12-65.65 (-78.62 to -48.40)-47.24 (-63.60 to -27.20)-23.36 (-45.43 to 1.67)
Statistical analysis
  • Denosumab 60 mg vs Placebo · van Elteren Stratified Rank Test · p = <0.001
  • Denosumab 180 mg vs Placebo · van Elteren Stratified Rank Test · p = <0.001
SecondaryPercent Change From Baseline in Procollagen 1 N-terminal Peptide (P1NP) at Month 3

Percent change from baseline to Month 3 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline, Month 3
Reported as:
Median · Percent change from baseline
Percent Change From Baseline in Procollagen 1 N-terminal Peptide (P1NP) at Month 3
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in Procollagen 1 N-terminal Peptide (P1NP) at Month 3-55.08 (-69.30 to -44.40)-57.57 (-70.07 to -46.07)-12.23 (-21.57 to -0.11)
Statistical analysis
  • Denosumab 60 mg vs Placebo · van Elteren Stratified Rank Test · p = <0.001
  • Denosumab 180 mg vs Placebo · van Elteren Stratified Rank Test · p = <0.001
SecondaryPercent Change From Baseline in P1NP at Month 6

Percent change from baseline to Month 6 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline, Month 6
Reported as:
Median · Percent change from baseline
Percent Change From Baseline in P1NP at Month 6
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in P1NP at Month 6-57.06 (-67.17 to -37.13)-51.57 (-64.51 to -37.35)-22.17 (-39.69 to -3.07)
Statistical analysis
  • Denosumab 60 mg vs Placebo · van Elteren Stratified Rank Test · p = <0.001
  • Denosumab 180 mg vs Placebo · van Elteren Stratified Rank Test · p = <0.001
SecondaryPercent Change From Baseline in P1NP at Month 12

Percent change from baseline to Month 12 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline, Month 12
Reported as:
Median · Percent change from baseline
Percent Change From Baseline in P1NP at Month 12
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in P1NP at Month 12-45.84 (-61.36 to -30.09)-41.8 (-57.30 to -18.89)-17.53 (-31.42 to -0.02)
Statistical analysis
  • Denosumab 60 mg vs Placebo · van Elteren Stratified Rank Test · p = 0.016
  • Denosumab 180 mg vs Placebo · van Elteren Stratified Rank Test · p = <0.001
SecondaryPercent Change From Baseline in Urine Type II Collagen C-telopeptide (C-Tx) /Creatinine at Month 3

Percent change from baseline to Month 3 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline, Month 3
Reported as:
Median · Percent change from baseline
Percent Change From Baseline in Urine Type II Collagen C-telopeptide (C-Tx) /Creatinine at Month 3
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in Urine Type II Collagen C-telopeptide (C-Tx) /Creatinine at Month 3-46.59 (-71.58 to 4.17)-35.8 (-56.80 to 16.99)2.71 (-24.18 to 31.72)
Statistical analysis
  • Denosumab 180 mg vs Placebo · van Elteren Stratified Rank Test · p = <0.001
  • Denosumab 60 mg vs Placebo · van Elteren Stratified Rank Test · p = <0.001
SecondaryPercent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 6

Percent change from baseline to Month 6 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline, Month 6
Reported as:
Median · Percent change from baseline
Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 6
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 67.17 (-32.43 to 88.27)9.65 (-21.79 to 51.16)4.54 (-27.44 to 56.52)
Statistical analysis
  • Denosumab 60 mg vs Placebo · van Elteren Stratified Rank Test · p = 0.673
  • Denosumab 180 mg vs Placebo · van Elteren Stratified Rank Test · p = 0.589
SecondaryPercent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 12

Percent change from baseline to Month 12 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.

Time frame:
Baseline, Month 12
Reported as:
Median · Percent change from baseline
Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 12
Percent change from baselineDenosumab 180 mgDenosumab 60 mgPlacebo
Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 1236.92 (4.50 to 111.51)61.92 (-15.84 to 108.60)-3.93 (-37.70 to 126.65)
Statistical analysis
  • Denosumab 60 mg vs Placebo · van Elteren Stratified Rank Test · p = 0.175
  • Denosumab 180 mg vs Placebo · van Elteren Stratified Rank Test · p = 0.133
SecondaryNumber of Participants With Anti-Denosumab Binding Antibodies

Serum from participants was tested for antibodies to denosumab by immuoassay at months 1, 3, 6 and 12. The number of participants with anti-denosumab antibodies at any assessment is reported.

Time frame:
Assessed at Baseline and at Months 1, 3, 6 and 12.
Reported as:
Number · Participants
Number of Participants With Anti-Denosumab Binding Antibodies
ParticipantsDenosumab 180 mgDenosumab 60 mgPlacebo
Number of Participants With Anti-Denosumab Binding Antibodies402
SecondaryNumber of Participants With Anti-Denosumab Binding Antibody and Neutralizing Antibody

Serum from participants testing positive for anti-denosumab binding antibodies was tested in a cell-based bioassay for neutralizing activity against denosumab.

Time frame:
Baseline to Month 12
Reported as:
Number · Participants
Number of Participants With Anti-Denosumab Binding Antibody and Neutralizing Antibody
ParticipantsDenosumab 180 mgDenosumab 60 mgPlacebo
Number of Participants With Anti-Denosumab Binding Antibody and Neutralizing Antibody0—0
SecondaryChange From Baseline in Albumin at Month 1

Laboratory Chemistry Albumin

Time frame:
Baseline, month 1
Reported as:
Mean · g/L
Change From Baseline in Albumin at Month 1
g/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Albumin at Month 1-0.36 ± 2.29-0.24 ± 2.25-0.30 ± 2.21
SecondaryChange From Baseline in Albumin at Month 3

Laboratory chemistry albumin

Time frame:
Baseline, month 3
Reported as:
Mean · g/L
Change From Baseline in Albumin at Month 3
g/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Albumin at Month 3-0.30 ± 2.18-0.12 ± 2.28-0.18 ± 2.07
SecondaryChange From Baseline in Albumin at Month 6

Laboratory chemistry albumin

Time frame:
Baseline, month 6
Reported as:
Mean · g/L
Change From Baseline in Albumin at Month 6
g/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Albumin at Month 6-0.30 ± 2.49-0.90 ± 2.56-0.77 ± 2.40
SecondaryChange From Baseline in Albumin at Month 12

Laboratory chemistry albumin

Time frame:
Baseline, month 12
Reported as:
Mean · g/L
Change From Baseline in Albumin at Month 12
g/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Albumin at Month 12-0.13 ± 2.41-0.06 ± 2.26-0.59 ± 2.49
SecondaryChange From Baseline in Alkaline Phosphatase at Month 1

Laboratory chemistry alkaline phoshatatse

Time frame:
Baseline, month 1
Reported as:
Mean · U/L
Change From Baseline in Alkaline Phosphatase at Month 1
U/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Alkaline Phosphatase at Month 1-5.87 ± 10.52-3.66 ± 11.971.18 ± 15.62
SecondaryChange From Baseline in Alkaline Phosphatase at Month 3

Laboratory chemisrty alkaline phosphatase

Time frame:
baseline, month 3
Reported as:
Mean · U/L
Change From Baseline in Alkaline Phosphatase at Month 3
U/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Alkaline Phosphatase at Month 3-13.27 ± 15.91-12.38 ± 13.09-2.03 ± 8.37
SecondaryChange From Baseline in Alkaline Phosphatase at Month 6

Laboratory chemistry alkaline phosphatase

Time frame:
baseline, month 6
Reported as:
Mean · U/L
Change From Baseline in Alkaline Phosphatase at Month 6
U/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Alkaline Phosphatase at Month 6-7.84 ± 31.94-12.49 ± 12.61-0.54 ± 18.46
SecondaryChange From Baseline in Alkaline Phosphatase at Month 12

Laboratory chemistry alkaline phosphatase

Time frame:
baseine, month 12
Reported as:
Mean · U/L
Change From Baseline in Alkaline Phosphatase at Month 12
U/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Alkaline Phosphatase at Month 12-11.92 ± 16.74-11.34 ± 18.18-4.63 ± 16.70
SecondaryChange From Baseline in Bicarbonate at Month 1

Laboratory chemistry bicarbonate

Time frame:
baseline, month 1
Reported as:
Mean · mmol/L
Change From Baseline in Bicarbonate at Month 1
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Bicarbonate at Month 10.78 ± 2.310.06 ± 3.060.54 ± 2.94
SecondaryChange From Baseline in Bicarbonate at Month 3

Laboratory chemistry bicarbonate

Time frame:
baseline, month 3
Reported as:
Mean · mmol/L
Change From Baseline in Bicarbonate at Month 3
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Bicarbonate at Month 30.12 ± 2.400.39 ± 2.84-0.67 ± 3.17
SecondaryChange From Baseline in Bicarbonate at Month 6

Laboratory chemistry bicarbonate

Time frame:
Baseline, month 6
Reported as:
Mean · mmol/L
Change From Baseline in Bicarbonate at Month 6
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Bicarbonate at Month 60.45 ± 2.29-0.12 ± 2.61-0.18 ± 2.67
SecondaryChange From Baseline in Bicarbonate at Month 12

Laboratory chemistry bicarbonate

Time frame:
Baseline, Month 12
Reported as:
Mean · mmol/L
Change From Baseline in Bicarbonate at Month 12
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Bicarbonate at Month 120.81 ± 2.120.58 ± 2.680.23 ± 2.50
SecondaryChange From Baseline in Total Bilirubin at Month 1

Laboratory chemistry total bilirubin

Time frame:
baseline, month 1
Reported as:
Mean · umol/L
Change From Baseline in Total Bilirubin at Month 1
umol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Total Bilirubin at Month 10.26 ± 2.39-0.23 ± 2.450.42 ± 2.83
SecondaryChange From Baseline in Total Bilirubin at Month 3

Laboratory chemistry total bilirubin

Time frame:
Baseline, month 3
Reported as:
Mean · umol/L
Change From Baseline in Total Bilirubin at Month 3
umol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Total Bilirubin at Month 30.92 ± 2.17-0.23 ± 2.360.44 ± 2.74
SecondaryChange From Baseline in Total Bilirubin at Month 6

Laboratory chemistry total bilirubin

Time frame:
Baseline, month 6
Reported as:
Mean · umol/L
Change From Baseline in Total Bilirubin at Month 6
umol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Total Bilirubin at Month 61.08 ± 2.58-0.61 ± 2.490.34 ± 3.30
SecondaryChange From Baseline in Total Bilirubin at Month 12

Laboratory chemistry total bilirubin

Time frame:
Baseline, month 12
Reported as:
Mean · umol/L
Change From Baseline in Total Bilirubin at Month 12
umol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Total Bilirubin at Month 120.41 ± 2.58-0.35 ± 2.280.03 ± 2.80
SecondaryChange From Baseline in Blood Urea Nitrogen at Month 1

Laboratory chemistry blood urea nitrogen

Time frame:
Baseline, month 1
Reported as:
Mean · mmol/L
Change From Baseline in Blood Urea Nitrogen at Month 1
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Blood Urea Nitrogen at Month 10 ± 1.350.15 ± 1.40-0.01 ± 1.55
SecondaryChange From Baseline in Blood Urea Nitrogen at Month 3

Laboratory chemistry blood urea nitrogen

Time frame:
Baseline, month 3
Reported as:
Mean · mmol/L
Change From Baseline in Blood Urea Nitrogen at Month 3
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Blood Urea Nitrogen at Month 30.04 ± 1.350.41 ± 1.590.06 ± 1.43
SecondaryChange From Baseline in Blood Urea Nitrogen at Month 6

Laboratory chemistry blood urea nitrogen

Time frame:
Baseline, month 6
Reported as:
Mean · mmol/L
Change From Baseline in Blood Urea Nitrogen at Month 6
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Blood Urea Nitrogen at Month 6-0.21 ± 1.44-0.08 ± 1.41-0.04 ± 2.29
SecondaryChange From Baseline in Blood Urea Nitrogen at Month 12

Laboratory chemistry blood urea nitrogen

Time frame:
baseline, month 12
Reported as:
Mean · mmol/L
Change From Baseline in Blood Urea Nitrogen at Month 12
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Blood Urea Nitrogen at Month 120.32 ± 1.370.24 ± 1.46-0.09 ± 1.56
SecondaryChange From Baseline in Calcium at Month 1

Laboratory chemistry calcium

Time frame:
baseline. month 1
Reported as:
Mean · mmol/L
Change From Baseline in Calcium at Month 1
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Calcium at Month 1-0.05 ± 0.11-0.05 ± 0.090.01 ± 0.09
SecondaryChange From Baseline in Calcium at Month 3

Laboratory chemistry calcium

Time frame:
Baseline, month 3
Reported as:
Mean · mmol/L
Change From Baseline in Calcium at Month 3
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Calcium at Month 3-0.01 ± 0.11-0.02 ± 0.100 ± 0.10
SecondaryChange From Baseline in Calcium at Month 6

Laboratory chemistry calcium

Time frame:
baseline, month 6
Reported as:
Mean · mmol/L
Change From Baseline in Calcium at Month 6
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Calcium at Month 6-0.01 ± 0.10-0.03 ± 0.11-0.01 ± 0.10
SecondaryChange From Baseline in Calcium at Month 12

Laboratory chemistry calcium

Time frame:
Baseline, month 12
Reported as:
Mean · mmol/L
Change From Baseline in Calcium at Month 12
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Calcium at Month 12-0.01 ± 0.110.01 ± 0.090.01 ± 0.08
SecondaryChange From Baseline in Calcium (Corrected) at Month 1

Laboratory chemistry albumin-adjusted calcium

Time frame:
Baseline, month 1
Reported as:
Mean · mmol/L
Change From Baseline in Calcium (Corrected) at Month 1
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Calcium (Corrected) at Month 1-0.05 ± 0.11-0.05 ± 0.090.01 ± 0.09
SecondaryChange From Baseline in Calcium (Corrected) at Month 3

Laboratory chemistry albumin-adjusted calcium

Time frame:
baseline, month 3
Reported as:
Mean · mmol/L
Change From Baseline in Calcium (Corrected) at Month 3
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Calcium (Corrected) at Month 3-0.01 ± 0.11-0.02 ± 0.090 ± 0.10
SecondaryChange From Baseline in Calcium (Corrected) at Month 6

Laboratory chemistry albumin-adjusted calcium

Time frame:
Baseline, Month 6
Reported as:
Mean · mmol/L
Change From Baseline in Calcium (Corrected) at Month 6
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Calcium (Corrected) at Month 6-0.01 ± 0.10-0.02 ± 0.10-0.01 ± 0.09
SecondaryChange From Baseline in Calcium (Corrected) at Month 12

Laboratory chemistry albumin-adjusted calcium

Time frame:
Baselien, Month 12
Reported as:
Mean · mmol/L
Change From Baseline in Calcium (Corrected) at Month 12
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Calcium (Corrected) at Month 12-0.01 ± 0.110.01 ± 0.090 ± 0.08
SecondaryChange From Baseline in Chloride at Month 1

Laboratory chemistry chloride

Time frame:
baseline, month 1
Reported as:
Mean · mmol/L
Change From Baseline in Chloride at Month 1
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Chloride at Month 10.24 ± 2.360.58 ± 2.660.01 ± 2.09
SecondaryChange From Baseline in Chloride at Month 3

Laboratory chemistry chloride

Time frame:
Baseline, month 3
Reported as:
Mean · mmol/L
Change From Baseline in Chloride at Month 3
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Chloride at Month 3-0.01 ± 2.670.38 ± 2.350.78 ± 2.20
SecondaryChange From Baseline in Chloride at Month 6

Laboratory chemistry chloride

Time frame:
Baseline, month 6
Reported as:
Mean · mmol/L
Change From Baseline in Chloride at Month 6
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Chloride at Month 6-0.57 ± 2.850.48 ± 2.190 ± 2.79
SecondaryChange From Baseline in Chloride at Month 12

Laboratory chemistry chloride

Time frame:
Baseline, month 12
Reported as:
Mean · mmol/L
Change From Baseline in Chloride at Month 12
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Chloride at Month 12-0.62 ± 2.45-0.21 ± 2.58-0.08 ± 2.39
SecondaryChange From Baseline in Creatinine at Month 1

Laboratory chemistry creatinine

Time frame:
Baseline, month 1
Reported as:
Mean · µmol/L
Change From Baseline in Creatinine at Month 1
µmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Creatinine at Month 1-0.88 ± 9.890.38 ± 8.631.47 ± 8.78
SecondaryChange From Baseline in Creatinine at Month 3

Laboratory chemistry creatinine

Time frame:
Baseline, month 3
Reported as:
Mean · µmol/L
Change From Baseline in Creatinine at Month 3
µmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Creatinine at Month 30.62 ± 11.113.20 ± 8.303.81 ± 9.24
SecondaryChange From Baseline in Creatinine at Month 6

Laboratory chemistry creatinine

Time frame:
Baseline, month 6
Reported as:
Mean · µmol/L
Change From Baseline in Creatinine at Month 6
µmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Creatinine at Month 63.30 ± 10.973.84 ± 9.883.54 ± 11.60
SecondaryChange From Baseline in Creatinine at Month 12

Laboratory chemistry creatinine

Time frame:
Baseline, month 12
Reported as:
Mean · µmol/L
Change From Baseline in Creatinine at Month 12
µmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Creatinine at Month 125.44 ± 10.094.42 ± 9.593.73 ± 7.84
SecondaryChange From Baseline in Gamma-Glutamyl Transferase at Month 1

Laboratory chemistry gamma-glutamyl transferase

Time frame:
Baseline, month 1
Reported as:
Mean · U/L
Change From Baseline in Gamma-Glutamyl Transferase at Month 1
U/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Gamma-Glutamyl Transferase at Month 11.04 ± 8.13-1.25 ± 9.670.26 ± 10.63
SecondaryChange From Baseline in Gamma-Glutamyl Transferase at Month 3

Laboratory chemistry gamma-glutamyl transferase

Time frame:
Baseline, month 3
Reported as:
Mean · U/L
Change From Baseline in Gamma-Glutamyl Transferase at Month 3
U/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Gamma-Glutamyl Transferase at Month 32.32 ± 10.940.04 ± 9.901.51 ± 15.87
SecondaryChange From Baseline in Gamma-Glutamyl Transferase at Month 6

Laboratory chemistry gamma-glutamyl transferase

Time frame:
Baseline, month 6
Reported as:
Mean · U/L
Change From Baseline in Gamma-Glutamyl Transferase at Month 6
U/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Gamma-Glutamyl Transferase at Month 67.37 ± 36.420.28 ± 12.705.67 ± 37.98
SecondaryChange From Baseline in Gamma-Glutamyl Transferase at Month 12

Laboratory chemistry gamma-glutamyl transferase

Time frame:
Baseline, month 12
Reported as:
Mean · U/L
Change From Baseline in Gamma-Glutamyl Transferase at Month 12
U/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Gamma-Glutamyl Transferase at Month 122.98 ± 10.941.08 ± 16.09-1.38 ± 14.70
SecondaryChange From Baseline in Glucose at Month 1

Laboratory chemistry glucose

Time frame:
Baseline, month 1
Reported as:
Mean · mmol/L
Change From Baseline in Glucose at Month 1
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Glucose at Month 10.06 ± 0.760.20 ± 0.650.05 ± 1.28
SecondaryChange From Baseline in Glucose at Month 3

Laboratory chemistry glucose

Time frame:
Baseline, month 3
Reported as:
Mean · mmol/L
Change From Baseline in Glucose at Month 3
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Glucose at Month 30.08 ± 0.870.20 ± 0.630.04 ± 1.26
SecondaryChange From Baseline in Glucose at Month 6

Laboratory chemistry glucose

Time frame:
Baseline, month 6
Reported as:
Mean · mmol/L
Change From Baseline in Glucose at Month 6
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Glucose at Month 60.12 ± 0.850.20 ± 0.65-0.05 ± 1.26
SecondaryChange From Baseline in Glucose at Month 12

Laboratory chemistry glucose

Time frame:
baseline, month 12
Reported as:
Mean · mmol/L
Change From Baseline in Glucose at Month 12
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Glucose at Month 12-0.04 ± 0.660.22 ± 0.960.19 ± 1.27
SecondaryChange From Baseline in Potassium at Month 1

Laboratory chemistry potassium

Time frame:
Baseline, month 1
Reported as:
Mean · mmol/L
Change From Baseline in Potassium at Month 1
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Potassium at Month 10.06 ± 0.380.06 ± 0.360.04 ± 0.36
SecondaryChange From Baseline in Potassium at Month 3

Laboratory chemistry potassium

Time frame:
Baseline, month 3
Reported as:
Mean · mmol/L
Change From Baseline in Potassium at Month 3
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Potassium at Month 3-0.01 ± 0.390.06 ± 0.400.04 ± 0.38
SecondaryChange From Baseline in Potassium at Month 6

Laboratory chemistry potassium

Time frame:
Baseline, month 6
Reported as:
Mean · mmol/L
Change From Baseline in Potassium at Month 6
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Potassium at Month 60.01 ± 0.44-0.01 ± 0.360 ± 0.42
SecondaryChange From Baseline in Potassium at Month 12

Laboratory chemistry potassium

Time frame:
Baseline, month 12
Reported as:
Mean · mmol/L
Change From Baseline in Potassium at Month 12
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Potassium at Month 12-0.07 ± 0.44-0.08 ± 0.35-0.04 ± 0.43
SecondaryChange From Baseline in Magnesium at Month 1

Laboratory chemistry magnesium

Time frame:
Baseline, month 1
Reported as:
Mean · mmol/L
Change From Baseline in Magnesium at Month 1
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Magnesium at Month 10.01 ± 0.060.02 ± 0.060.01 ± 0.05
SecondaryChange From Baseline in Magnesium at Month 3

Laboratory chemistry magnesium

Time frame:
Baseline, month 3
Reported as:
Mean · mmol/L
Change From Baseline in Magnesium at Month 3
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Magnesium at Month 3-0.01 ± 0.060.02 ± 0.060 ± 0.06
SecondaryChange From Baseline in Magnesium at Month 6

Laboratory chemistry magnesium

Time frame:
Baseline, month 6
Reported as:
Mean · mmol/L
Change From Baseline in Magnesium at Month 6
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Magnesium at Month 60 ± 0.060.01 ± 0.060.01 ± 0.07
SecondaryChange From Baseline in Magnesium at Month 12

Laboratory chemistry magnesium

Time frame:
Baseline, month 12
Reported as:
Mean · mmol/L
Change From Baseline in Magnesium at Month 12
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Magnesium at Month 12-0.01 ± 0.06-0.01 ± 0.07-0.01 ± 0.08
SecondaryChange From Baseline in Sodium at Month 1

Laboratory chemistry sodium

Time frame:
Baseline, month 1
Reported as:
Mean · mmol/L
Change From Baseline in Sodium at Month 1
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Sodium at Month 1-0.03 ± 1.93-0.06 ± 2.620.33 ± 2.03
SecondaryChange From Baseline in Sodium at Month 3

Change From Baseline in Sodium at Month 3

Time frame:
Baseline, Month 3
Reported as:
Mean · mmol/L
Change From Baseline in Sodium at Month 3
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Sodium at Month 3-0.14 ± 2.13-0.16 ± 2.290.39 ± 2.38
SecondaryChange From Baseline in Sodium at Month 6

Laboratory chemistry sodium

Time frame:
Baseline, month 6
Reported as:
Mean · mmol/L
Change From Baseline in Sodium at Month 6
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Sodium at Month 6-0.12 ± 1.98-0.06 ± 1.750.03 ± 2.27
SecondaryChange From Baseline in Sodium at Month 12

Laboratory chemistry sodium

Time frame:
Baseline, month 12
Reported as:
Mean · mmol/L
Change From Baseline in Sodium at Month 12
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Sodium at Month 12-0.25 ± 2.02-0.27 ± 2.750.33 ± 2.38
SecondaryChange From Baseline in Phosphorus at Month 1

Laboratory chemistry phosphorus

Time frame:
Baseline, month 1
Reported as:
Mean · mmol/L
Change From Baseline in Phosphorus at Month 1
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Phosphorus at Month 1-0.09 ± 0.16-0.06 ± 0.190.02 ± 0.14
SecondaryChange From Baseline in Phosphorus at Month 3

Laboratory chemistry phosphorus

Time frame:
Baseline, month 3
Reported as:
Mean · mmol/L
Change From Baseline in Phosphorus at Month 3
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Phosphorus at Month 3-0.03 ± 0.16-0.03 ± 0.180.01 ± 0.20
SecondaryChange From Baseline in Phosphorus at Month 6

Laboratory chemistry phosphorus

Time frame:
Baseline, month 6
Reported as:
Mean · mmol/L
Change From Baseline in Phosphorus at Month 6
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Phosphorus at Month 6-0.05 ± 0.17-0.01 ± 0.180.03 ± 0.19
SecondaryChange From Baseline in Phosphorus at Month 12

Change From Baseline in Phosphorus at Month 12

Time frame:
Baseline, month 12
Reported as:
Mean · mmol/L
Change From Baseline in Phosphorus at Month 12
mmol/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Phosphorus at Month 12-0.05 ± 0.170 ± 0.170 ± 0.16
SecondaryChange From Baseline in Total Protein at Month 1

Laboratory chemistry total protein

Time frame:
Baseline, month 1
Reported as:
Mean · g/L
Change From Baseline in Total Protein at Month 1
g/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Total Protein at Month 1-0.46 ± 3.56-0.40 ± 3.220.21 ± 3.00
SecondaryChange From Baseline in Total Protein at Month 3

Laboratory chemistry total protein

Time frame:
Baseline, month 3
Reported as:
Mean · g/L
Change From Baseline in Total Protein at Month 3
g/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Total Protein at Month 3-0.29 ± 3.350.07 ± 3.42-0.20 ± 3.54
SecondaryChange From Baseline in Total Protein at Month 6

Laboratory chemistry total protein

Time frame:
Baseline, month 6
Reported as:
Mean · g/L
Change From Baseline in Total Protein at Month 6
g/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Total Protein at Month 6-0.09 ± 4.13-0.62 ± 3.40-0.57 ± 3.19
SecondaryChange From Baseline in Total Protein at Month 12

Laboratory chemistry total protein

Time frame:
Baseline, month 12
Reported as:
Mean · g/L
Change From Baseline in Total Protein at Month 12
g/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Total Protein at Month 12-0.97 ± 3.76-0.91 ± 3.55-0.98 ± 3.10
SecondaryChange From Baseline in Aspartate Amino Transferase at Month 1

Laboratory chemistry aspartate amino transferase

Time frame:
Baseline, month 1
Reported as:
Mean · U/L
Change From Baseline in Aspartate Amino Transferase at Month 1
U/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Aspartate Amino Transferase at Month 1-0.79 ± 5.84-0.26 ± 8.140.90 ± 8.35
SecondaryChange From Baseline in Aspartate Amino Transferase at Month 3

Laboratory chemistry aspartate amino transferase

Time frame:
Baseline, month 3
Reported as:
Mean · U/L
Change From Baseline in Aspartate Amino Transferase at Month 3
U/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Aspartate Amino Transferase at Month 31.99 ± 5.770.40 ± 8.782.69 ± 9.37
SecondaryChange From Baseline in Aspartate Amino Transferase

Laboratory chemistry aspartate amino transferase

Time frame:
Baseline, month 6
Reported as:
Mean · U/L
Change From Baseline in Aspartate Amino Transferase
U/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Aspartate Amino Transferase3.85 ± 15.660.87 ± 7.583.24 ± 15.90
SecondaryChange From Baseline in Aspartate Amino Transferase at Month 12

Laboratory chemistry aspartate amino transferase

Time frame:
Baseline, month 12
Reported as:
Mean · U/L
Change From Baseline in Aspartate Amino Transferase at Month 12
U/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Aspartate Amino Transferase at Month 123.86 ± 18.623.75 ± 18.112.24 ± 7.32
SecondaryChange From Baseline in Alanine Amino Transferase at Month 1

Laboratory chemistry alanine amino transferase

Time frame:
Baseline, month 1
Reported as:
Mean · U/L
Change From Baseline in Alanine Amino Transferase at Month 1
U/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Alanine Amino Transferase at Month 1-1.84 ± 8.61-1.03 ± 12.371.20 ± 15.44
SecondaryChange From Baseline in Alanine Amino Transferase at Month 3

Laboratory Chemistry alanine amino transferase

Time frame:
Baseline, month 3
Reported as:
Mean · U/L
Change From Baseline in Alanine Amino Transferase at Month 3
U/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Alanine Amino Transferase at Month 30.04 ± 8.85-2.10 ± 14.341.54 ± 13.00
SecondaryChange From Baseline in Alanine Amino Transferase at Month 6

Laboratory chemistry alanine amino transferase

Time frame:
Baseline, month 6
Reported as:
Mean · U/L
Change From Baseline in Alanine Amino Transferase at Month 6
U/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Alanine Amino Transferase at Month 61.20 ± 15.83-1.76 ± 14.125.44 ± 51.19
SecondaryChange From Baseline in Alanine Amino Transferase at Month 12

Laboratory chemistry alanine amino transferase

Time frame:
Baseline, month 12
Reported as:
Mean · U/L
Change From Baseline in Alanine Amino Transferase at Month 12
U/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Alanine Amino Transferase at Month 124.86 ± 24.461.66 ± 14.301.82 ± 14.41
SecondaryChange From Baseline in Basophils at Month 1

Laboratory hematology basophils

Time frame:
baseline, month 1
Reported as:
Mean · *10^9/L
Change From Baseline in Basophils at Month 1
*10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Basophils at Month 10 ± 0.070 ± 0.07-0.01 ± 0.07
SecondaryChange From Baseline in Basophils at Month 3

Laboratory hematology basophils

Time frame:
Baseline, month 3
Reported as:
Mean · * 10^9/L
Change From Baseline in Basophils at Month 3
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Basophils at Month 3-0.01 ± 0.06-0.01 ± 0.07-0.01 ± 0.07
SecondaryChange From Baseline in Basophils at Month 6

Laboratory hematology basophils

Time frame:
Baseline, month 6
Reported as:
Mean · * 10^9/L
Change From Baseline in Basophils at Month 6
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Basophils at Month 60 ± 0.060 ± 0.070 ± 0.06
SecondaryChange From Baseline in Basophils at Month 12

Laboratory hematology basophils

Time frame:
Baseline, month 12
Reported as:
Mean · * 10^9/L
Change From Baseline in Basophils at Month 12
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Basophils at Month 120.02 ± 0.090 ± 0.090.03 ± 0.07
SecondaryChange From Baseline in Eosinophils at Month 1

Laboratory hematology eosinophils

Time frame:
Baseline, month 1
Reported as:
Mean · * 10^9/L
Change From Baseline in Eosinophils at Month 1
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Eosinophils at Month 1-0.02 ± 0.09-0.01 ± 0.090.01 ± 0.08
SecondaryChange From Baseline in Eosinophils at Month 3

Laboratory hematology eosinophils

Time frame:
Baseline, month 3
Reported as:
Mean · * 10^9/L
Change From Baseline in Eosinophils at Month 3
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Eosinophils at Month 30 ± 0.100 ± 0.10-0.01 ± 0.09
SecondaryChange From Baseline in Eosinophils at Month 6

Laboratory hematology eosinophils

Time frame:
Baseline, month 6
Reported as:
Mean · * 10^9/L
Change From Baseline in Eosinophils at Month 6
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Eosinophils at Month 6-0.03 ± 0.090 ± 0.130 ± 0.13
SecondaryChange From Baseline in Eosinophils at Month 12

Laboratory hematology eosinophils

Time frame:
Baseline, month 12
Reported as:
Mean · * 10^9/L
Change From Baseline in Eosinophils at Month 12
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Eosinophils at Month 120.03 ± 0.160.02 ± 0.120.01 ± 0.12
SecondaryChange From Baseline in Hematocrit at Month 1

Laboratory hematology hematocrit

Time frame:
Baseline, month 1
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematocrit at Month 1
Proportion of red blood cells in bloodDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Hematocrit at Month 10 ± 0.020 ± 0.020 ± 0.02
SecondaryChange From Baseline in Hematocrit at Month 3

Laboratory hematology hematocrit

Time frame:
Baseline, month 3
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematocrit at Month 3
Proportion of red blood cells in bloodDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Hematocrit at Month 30.01 ± 0.020 ± 0.030 ± 0.03
SecondaryChange From Baseline in Hematocrit at Month 6

Laboratory hematology hematocrit

Time frame:
Baseline, month 6
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematocrit at Month 6
Proportion of red blood cells in bloodDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Hematocrit at Month 60.01 ± 0.020 ± 0.030 ± 0.03
SecondaryChange From Baseline in Hematocrit at Month 12

Laboratory hematology hematocrit

Time frame:
Baseline, month 12
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematocrit at Month 12
Proportion of red blood cells in bloodDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Hematocrit at Month 120 ± 0.020 ± 0.03-0.01 ± 0.03
SecondaryChange From Baseline in Hemoglobin at Month 1

Laboratory hematology hemoglobin

Time frame:
Baseline, month 1
Reported as:
Mean · g/L
Change From Baseline in Hemoglobin at Month 1
g/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Hemoglobin at Month 1-0.33 ± 6.73-1.48 ± 6.39-0.69 ± 6.34
SecondaryChange From Baseline in Hemoglobin at Month 3

Laboratory hematology hemoglobin

Time frame:
Baseline, month 3
Reported as:
Mean · g/L
Change From Baseline in Hemoglobin at Month 3
g/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Hemoglobin at Month 30.69 ± 7.02-1.02 ± 8.36-1.10 ± 6.30
SecondaryChange From Baseline in Hemoglobin at Month 6

Laboratory hematology hemoglobin

Time frame:
Baseline, month 6
Reported as:
Mean · g/L
Change From Baseline in Hemoglobin at Month 6
g/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Hemoglobin at Month 6-0.36 ± 7.80-1.69 ± 8.82-0.69 ± 8.21
SecondaryChange From Baseline in Hemoglobin at Month 12

Laboratory hematology hemoglobin

Time frame:
Baseline, month 12
Reported as:
Mean · g/L
Change From Baseline in Hemoglobin at Month 12
g/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Hemoglobin at Month 121.21 ± 9.260.02 ± 11.66-0.46 ± 10.08
SecondaryChange From Baseline in Lymphocytes at Month 1

Laboratory hematology lymphocytes

Time frame:
Baseline, month 1
Reported as:
Mean · * 10^9/L
Change From Baseline in Lymphocytes at Month 1
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Lymphocytes at Month 1-0.02 ± 0.410.10 ± 0.400 ± 0.45
SecondaryChange From Baseline in Lymphocytes at Month 3

Laboratory hematology lymphocytes

Time frame:
Baseline, month 3
Reported as:
Mean · * 10^9/L
Change From Baseline in Lymphocytes at Month 3
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Lymphocytes at Month 30.07 ± 0.380.14 ± 0.480.08 ± 0.46
SecondaryChange From Baseline in Lymphocytes at Month 6

Laboratory hematology lymphocytes

Time frame:
Baseline, month 6
Reported as:
Mean · * 10^9/L
Change From Baseline in Lymphocytes at Month 6
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Lymphocytes at Month 60.12 ± 0.410.05 ± 0.350.03 ± 0.68
SecondaryChange From Baseline in Lymphocytes at Month 12

Laboratory hematology lymphocytes

Time frame:
Baseline, month 12
Reported as:
Mean · * 10^9/L
Change From Baseline in Lymphocytes at Month 12
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Lymphocytes at Month 12-0.02 ± 0.490.04 ± 0.50-0.02 ± 0.49
SecondaryChange From Baseline in Monocytes at Month 1

Laboratory hematology monocytes

Time frame:
Baseline, month 1
Reported as:
Mean · * 10^9/L
Change From Baseline in Monocytes at Month 1
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Monocytes at Month 10.01 ± 0.13-0.01 ± 0.100.01 ± 0.12
SecondaryChange From Baseline in Monocytes at Month 3

Laboratory hematology monocytes

Time frame:
Baseline, month 3
Reported as:
Mean · * 10^9/L
Change From Baseline in Monocytes at Month 3
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Monocytes at Month 30.02 ± 0.110.01 ± 0.110.02 ± 0.11
SecondaryChange From Baseline in Monocytes at Month 6

Laboratory hematology monocytes

Time frame:
Baseline, month 6
Reported as:
Mean · * 10^9/L
Change From Baseline in Monocytes at Month 6
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Monocytes at Month 60.05 ± 0.170.04 ± 0.120.04 ± 0.13
SecondaryChange From Baseline in Monocytes at Month 12

Laboratory hematology monocytes

Time frame:
Baseline, month 12
Reported as:
Mean · * 10^9/L
Change From Baseline in Monocytes at Month 12
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Monocytes at Month 120.03 ± 0.150 ± 0.110.02 ± 0.13
SecondaryChange From Baseline in Total Neutrophils at Month 1

Laboratory hematology total neutrophils

Time frame:
Baseline, month 1
Reported as:
Mean · * 10^9/L
Change From Baseline in Total Neutrophils at Month 1
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Total Neutrophils at Month 10 ± 1.970.18 ± 1.99-0.13 ± 1.68
SecondaryChange From Baseline in Total Neutrophils at Month 3

Laboratory hematology total neutrophils

Time frame:
Baseline, month 3
Reported as:
Mean · * 10^9/L
Change From Baseline in Total Neutrophils at Month 3
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Total Neutrophils at Month 30.11 ± 1.920.26 ± 1.64-0.11 ± 1.55
SecondaryChange From Baseline in Total Neutrophils at Month 6

Laboratory hematology total neutrophils

Time frame:
Baseline, month 6
Reported as:
Mean · * 10^9/L
Change From Baseline in Total Neutrophils at Month 6
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Total Neutrophils at Month 60.18 ± 1.67-0.05 ± 1.660.27 ± 2.36
SecondaryChange From Baseline in Total Neutrophils at Month 12

Laboratory hematology total neutrophils

Time frame:
Baseline, month 12
Reported as:
Mean · * 10^9/L
Change From Baseline in Total Neutrophils at Month 12
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Total Neutrophils at Month 120.65 ± 2.370.04 ± 1.790.10 ± 2.31
SecondaryChange From Baseline in Platelets at Month 1

Laboratory hematology platelets

Time frame:
Baseline, month 1
Reported as:
Mean · * 10^9/L
Change From Baseline in Platelets at Month 1
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Platelets at Month 11.78 ± 44.5310.36 ± 49.342.96 ± 44.15
SecondaryChange From Baseline in Platelets at Month 3

Laboratory hematology platelets

Time frame:
Baseline, month 3
Reported as:
Mean · * 10^9/L
Change From Baseline in Platelets at Month 3
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Platelets at Month 3-2.82 ± 48.866.86 ± 50.18-1.97 ± 45.94
SecondaryChange From Baseline in Platelets at Month 6

Laboratory hematology platelets

Time frame:
Baseline, month 6
Reported as:
Mean · * 10^9/L
Change From Baseline in Platelets at Month 6
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Platelets at Month 61.95 ± 54.951.00 ± 45.641.57 ± 53.39
SecondaryChange From Baseline in Platelets at Month 12

Laboratory hematology platelets

Time frame:
Baseline, month 12
Reported as:
Mean · * 10^9/L
Change From Baseline in Platelets at Month 12
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Platelets at Month 123.32 ± 51.66-4.26 ± 51.121.07 ± 58.16
SecondaryChange From Baseline in Red Blood Cells at Month 1

Laboratory hematology red blood cells

Time frame:
Baseline, month 1
Reported as:
Mean · * 10^9/L
Change From Baseline in Red Blood Cells at Month 1
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Red Blood Cells at Month 1-0.01 ± 0.21-0.01 ± 0.20-0.01 ± 0.19
SecondaryChange From Baseline in Red Blood Cells at Month 3

Laboratory hematology red blood cells

Time frame:
Baseline, month 3
Reported as:
Mean · * 10^9/L
Change From Baseline in Red Blood Cells at Month 3
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Red Blood Cells at Month 30.05 ± 0.230.02 ± 0.280 ± 0.23
SecondaryChange From Baseline in Red Blood Cells at Month 6

Laboratory hematology red blood cells

Time frame:
Baseline, month 6
Reported as:
Mean · * 10^9/L
Change From Baseline in Red Blood Cells at Month 6
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Red Blood Cells at Month 60.01 ± 0.24-0.04 ± 0.260.01 ± 0.26
SecondaryChange From Baseline in Red Blood Cells at Month 12

Laboratory hematology red blood cells

Time frame:
Baseline, month 12
Reported as:
Mean · * 10^9/L
Change From Baseline in Red Blood Cells at Month 12
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in Red Blood Cells at Month 120.01 ± 0.27-0.06 ± 0.30-0.03 ± 0.29
SecondaryChange From Baseline in White Blood Cells at Month 1

Laboratory hematology white blood cells

Time frame:
Baseline, month 1
Reported as:
Mean · * 10^9/L
Change From Baseline in White Blood Cells at Month 1
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in White Blood Cells at Month 1-0.03 ± 2.070.26 ± 2.04-0.10 ± 1.88
SecondaryChange From Baseline in White Blood Cells at Month 3

Laboratpry hematology white blood cells

Time frame:
Baseline, month 3
Reported as:
Mean · * 10^9/L
Change From Baseline in White Blood Cells at Month 3
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in White Blood Cells at Month 30.18 ± 1.930.40 ± 1.71-0.05 ± 1.64
SecondaryChange From Baseline in White Blood Cells at Month 6

Laboratory hematology white blood cells

Time frame:
Baseline, month 6
Reported as:
Mean · * 10^9/L
Change From Baseline in White Blood Cells at Month 6
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in White Blood Cells at Month 60.30 ± 1.780.04 ± 1.850.35 ± 2.34
SecondaryChange From Baseline in White Blood Cells at Month 12

Laboratory hematology white blood cells

Time frame:
Baseline, month 12
Reported as:
Mean · * 10^9/L
Change From Baseline in White Blood Cells at Month 12
* 10^9/LDenosumab 180 mgDenosumab 60 mgPlacebo
Change From Baseline in White Blood Cells at Month 120.70 ± 2.400.11 ± 1.860.13 ± 2.22
SecondaryNumber of Participants With Laboratory Common Terminology Criteria for Adverse Events (CTCAE) Grade Greater or Equal to 3

Participants with laboratory toxicity of grade 3 or 4, graded according to the Common Terminology Criteria for Adverse Events, version 3.0, on the following general guideline: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death related to AE.

Time frame:
Month 1, month 3, month 6, month 12
Reported as:
Number · Participants
Number of Participants With Laboratory Common Terminology Criteria for Adverse Events (CTCAE) Grade Greater or Equal to 3
ParticipantsDenosumab 180 mgDenosumab 60 mgPlacebo
Alanine Amino Transferase-above normal (grade 3)001
Aspartate Amino Transferase-above normal (grade 3)010
Glucose-above normal (grade 3)100
Lymphocytes-below normal (grade 3)132
Sodium-below normal (grade 3)120
White Blood Cells-below normal (grade 3)011

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—5/75 (6.7%)47/75 (62.7%)
Denosumab 60 mg—3/71 (4.2%)44/71 (62%)
Denosumab 180 mg—6/72 (8.3%)44/72 (61.1%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventPlaceboDenosumab 60 mgDenosumab 180 mg
Myocardial infarctionCardiac disorders0/751/710/72
CellulitisInfections and infestations0/751/710/72
Humerus fractureInjury, poisoning and procedural complications0/751/710/72
Thermal burnInjury, poisoning and procedural complications0/751/710/72
ArthralgiaMusculoskeletal and connective tissue disorders0/751/710/72
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/751/710/72
Transient ischaemic attackNervous system disorders0/751/710/72
AnaemiaBlood and lymphatic system disorders0/750/711/72
Coronary artery diseaseCardiac disorders0/750/711/72
PyelonephritisInfections and infestations0/750/711/72
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlaceboDenosumab 60 mgDenosumab 180 mg
Rheumatoid arthritisMusculoskeletal and connective tissue disorders24/7522/7121/72
Upper respiratory tract infectionInfections and infestations6/7511/718/72
NasopharyngitisInfections and infestations9/755/715/72
SinusitisInfections and infestations8/754/718/72
FatigueGeneral disorders3/756/710/72
InfluenzaInfections and infestations0/752/716/72
CoughRespiratory, thoracic and mediastinal disorders5/755/711/72
Urinary tract infectionInfections and infestations1/754/713/72
ArthralgiaMusculoskeletal and connective tissue disorders3/754/712/72
BronchitisInfections and infestations3/753/714/72

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Denosumab 180 mgDenosumab 60 mgPlaceboTotal
Mean58 ± 1157.3 ± 11.457 ± 11.157.4 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab 180 mgDenosumab 60 mgPlaceboTotal
Female535162166
Male23221661
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Denosumab 180 mgDenosumab 60 mgPlaceboTotal
Asian1124
Japanese1012
American Indian or Alaska Native1214
White or Caucasian665962187
Black or African American1326
Hispanic or Latino66921
Native Hawaiian or Other Pacific Islander0011
Other0202
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R; Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008 May;58(5):1299-309. doi: 10.1002/art.23417. PubMed 18438830 ↗
  • Deodhar A, Dore RK, Mandel D, Schechtman J, Shergy W, Trapp R, Ory PA, Peterfy CG, Fuerst T, Wang H, Zhou L, Tsuji W, Newmark R. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2010 Apr;62(4):569-74. doi: 10.1002/acr.20004. PubMed 20391513 ↗
  • Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, Wang H, Tsuji W, Newmark R; Denosumab RA Study Group. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis. 2010 May;69(5):872-5. doi: 10.1136/ard.2009.112920. Epub 2009 Sep 3. PubMed 19734132 ↗
  • Sharp JT, Tsuji W, Ory P, Harper-Barek C, Wang H, Newmark R. Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care Res (Hoboken). 2010 Apr;62(4):537-44. doi: 10.1002/acr.20172. PubMed 20391509 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2004 to primary completion in Apr 2007, 31 months.

Results were first posted in Jan 2014, 6 years 9 months after primary completion. A results delay was requested in Nov 2009.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 31 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2004
First posted
Nov 8, 2004
StartActual
Aug 11, 2004
Primary completionActual
Apr 1, 2007
CompletionActual
Apr 1, 2007
Results delay requested
Nov 23, 2009
Results first posted
Jan 13, 2014
Last update
Oct 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00095498
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 8, 2004
Start date
Aug 11, 2004
Primary completion
Apr 1, 2007
Completion
Apr 1, 2007
Results posted
Jan 13, 2014
Last update
Oct 25, 2021

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion